ATTAIN-MAINTAIN completes, testing oral orforglipron after injected GLP-1 weight loss
A completed 376-person trial tested whether people who plateaued on injected GLP-1 drugs could hold their weight loss on a daily pill instead; results are not yet public.
The ATTAIN-MAINTAIN study has completed, closing out a 52-week test of a once-daily oral GLP-1 pill in people who had already lost weight on injectable drugs. The trial, registered as NCT06584916, enrolled 376 participants [1].
Everyone in the study had first taken part in SURMOUNT-5, a head-to-head comparison of two injected drugs: tirzepatide (sold as Mounjaro and Zepbound) and semaglutide (sold as Ozempic and Wegovy) [1]. To qualify for ATTAIN-MAINTAIN, participants had to have reached the highest dose of one of those injected drugs they could tolerate and then plateaued, meaning their weight had stopped falling [1].
At that point they were switched off the injectable and assigned to either once-daily oral orforglipron (Foundayo) or a placebo for 52 weeks [1]. The central question was whether the pill could hold steady the weight loss achieved with injections, and what happened to people who received placebo instead.
Those answers are not in the trial record. No results have been posted, and no topline findings have been released [1]. The dosing used in the study, the rate of side effects, and how many participants finished the 52 weeks have not been reported [1].
The study tests a switch, not a first-time treatment. It also does not compare orforglipron head-to-head against continuing an injection. That means even a positive result would say something specific: whether an oral drug can maintain weight loss after injected GLP-1 treatment stops.
Why it matters for patients
Stalled weight loss on an injected GLP-1 is a common point where patients and prescribers weigh options. ATTAIN-MAINTAIN is one of the first studies designed around that exact situation, and it tests a strategy that would not require a needle at all. An oral option could matter to people who dislike injections, have trouble with injection technique, or want to avoid the logistics that come with injectable products.
The placebo group is also informative. Those participants stopped their injected drug and took an inactive pill, so the study should show what happens to weight when treatment ends without a replacement. That information has not been released [1].
Nothing about this trial changes what is available today. Orforglipron remains an investigational drug in this setting; its regulatory status for weight management has not been reported in the study record [1]. Because no results have been posted, there is no evidence yet that switching from an injection to this pill works, keeps weight off, or is well tolerated. Any decision to stop or change a GLP-1 medication is a medical one, and a completed trial with unposted results does not provide the numbers a prescriber would need.
What happens next
The main milestone is results. Under federal reporting rules described on the registry, sponsors of applicable trials generally must submit results within one year of a study's primary completion date [1]. A results posting date for ATTAIN-MAINTAIN has not been disclosed, and no date for a medical conference presentation or journal publication has been reported [1].
The trial's full data — how much weight participants kept off on orforglipron versus placebo, and the side-effect profile over 52 weeks — will not be known until those results are released [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.